MOCA is very proud to announce that our fully organically grown crop of Cannabigerol (CBG) is now on the market in Australia.
Cannabigerol (CBG) is one of over 120 types of cannabinoids obtained from the cannabis plant.
Many have referred to CBG as the the next wave of medical cannabis that is about to gain in popularity as it is considered as the mother of all cannabinoids. Other cannabinoids are derived from cannabigerolic acid (CBGA), an acidic form of CBG.
CBG is processed by the body’s endocannabinoid system. The endocannabinoid system is made up of molecules and receptors in our bodies that are responsible for keeping our bodies in an optimal state.
When cannabis is harvested, dried and processed, in fact, the presence of this substance is detectable only in very small percentages (sometimes less than 1%), which is why it has not received particular attention compared to other substances.
Recently, however, it has been discovered that CBG is present in high percentages in the cannabis plant when it is at the beginning of the flowering phase and that it is the first substance to develop in the plant (in the acid form CBGA).
But not only that, it seems that the birth of THC, CBD and many other cannabinoids derives from CBG.
In the past, therefore, CBG was mainly known as a "minor cannabinoid", but today it has earned the nickname "cannabis stem cell".
In fact, as the plant matures, CBGA transforms into THCA, CBDA and CBCA.
When the plant is harvested and dried and manufactured, the action of heat generates a phenomenon called decarboxylation, which transforms CBGA derivatives into non-acid derivatives, namely THC, CBD and another hundred cannabinoids.
The production difficulties of CBG makes it very scarce. It’s much harder to produce than other cannabinoids like THC and CBD. Since CBG shares many similarities with CBD, manufacturers would rather produce CBD.
CBG has a host of promising potential benefits and more research is being done into easing the production and availability of the cannabinoid. CBG is growing in popularity as a result of the host of potential benefits the cannabinoid has to offer.
Cannabigerol is not scheduled by the UN Convention on Psychotropic Substances.
See overview of CBG research on this link and a literature overview of Cannabigerol on this link